Glaucoma, Neovascular
Conditions
Keywords
Neovascular, Glaucoma, Bevacizumab, Avastin, Intravitreal, IOP
Brief summary
Several studies have confirmed high levels of vascular endothelial growth factor (VEGF) in eyes with neovascular glaucoma (NVG). The role of VEGF inhibitors in regression of other neovascular disorders such as wet-type age-related macular degeneration and diabetic macular edema has been described. We aim to evaluate the effect of three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG. Outcome measures include intraocular pressure and extent of iris neovascularization. Both study arms will receive conventional treatment for NVG.
Interventions
OTHERsubconjunctival normal saline
0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
DRUGAvastin
intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
Sponsors
Shahid Beheshti University of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
10 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of NVG * Vision less than 20/200 * age 10-80 years
Exclusion criteria
* Uncontrolled Blood Pressure * History of thromboembolism * Congestive Heart Failure * Renal Failure * Pregnancy or Lactation * Active ocular or periocular infection * No light perception
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in intraocular pressure | 6 months |
| Change in extent of iris neovascularization | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity | 6 months |
Countries
Iran
Outcome results
None listed